Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0XEUXG
ADC Name
M25ADCMMAF
Synonyms
M25 ADC MMAF; M25-ADC-MMAF
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Pleural mesothelioma [ICD11:2C26]
Investigative
Drug-to-Antibody Ratio
3.3
Antibody Name
Anti-ALPPL2 mAb M25
  Antibody Info 
Antigen Name
Alkaline phosphatase, germ cell type (ALPG)
  Antigen Info 
Payload Name
Monomethyl auristatin F
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 62.3
%
M28K cells
Pleural malignant mesothelioma
Tumor Growth Inhibition value (TGI) 
≈ 69.16
%
M28K cells
Pleural malignant mesothelioma
Tumor Growth Inhibition value (TGI) 
≈ 97.72
%
M28K cells
Pleural malignant mesothelioma
Revealed Based on the Cell Line Data
Click To Hide/Show 5 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
0.4
nM
M28K cells
Pleural malignant mesothelioma
Half Maximal Effective Concentration (EC50) 
36
nM
VAMT-1 cells
Pleural sarcomatoid mesothelioma
Half Maximal Effective Concentration (EC50) 
> 100
nM
HK-2 [Human kidney] cells
Normal
Half Maximal Effective Concentration (EC50) 
> 100
nM
HS775Li cells
Normal
Half Maximal Effective Concentration (EC50) 
> 100
nM
HS-27 cells
Normal
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 62.30% (Day 31) Positive ALPPL2 expression (ALPPL2+++/++)
Method Description
Nude mice were subcutaneously (s.c.) implanted with one million M28 cells. When the average tumor volume reached 150 mm3, the mice were randomized into three study groups and treated intravenously (i.v.) with M25ADCMMAF for a total of 4 doses at 5 mg/kg.
In Vivo Model M28 CDX model
In Vitro Model Pleural malignant mesothelioma M28K cells CVCL_8106
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 69.16% (Day 32) Positive ALPPL2 expression (ALPPL2+++/++)
Method Description
Nude mice were subcutaneously (s.c.) implanted with one million M28 cells. When the average tumor volume reached 250 mm3, the mice were randomized into three study groups and treated intravenously (i.v.) with M25ADCMMAF for a total of 4 doses at 5 mg/kg.
In Vivo Model M28 CDX model
In Vitro Model Pleural malignant mesothelioma M28K cells CVCL_8106
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 97.72% (Day 37) Positive ALPPL2 expression (ALPPL2+++/++)
Method Description
Nude mice were subcutaneously (s.c.) implanted with one million M28 cells. When the average tumor volume reached 500 mm3, the mice were randomized into three study groups and treated intravenously (i.v.) with M25ADCMMAF for a total of 4 doses at 5 mg/kg.
In Vivo Model M28 CDX model
In Vitro Model Pleural malignant mesothelioma M28K cells CVCL_8106
Revealed Based on the Cell Line Data
Click To Hide/Show 5 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.40 nM Positive ALPPL2 expression (ALPPL2+++/++)
Method Description
Anti-ALPPL2 ADC and control ADC were assessed for cytotoxicity in vitro against mesothelioma (M28 and VAMT-1) and control cells (normal human fibroblasts, kidney cells, and primary liver cells).
In Vitro Model Pleural malignant mesothelioma M28K cells CVCL_8106
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 36.00 nM Positive ALPPL2 expression (ALPPL2+++/++)
Method Description
Anti-ALPPL2 ADC and control ADC were assessed for cytotoxicity in vitro against mesothelioma (M28 and VAMT-1) and control cells (normal human fibroblasts, kidney cells, and primary liver cells).
In Vitro Model Pleural sarcomatoid mesothelioma VAMT-1 cells CVCL_A731
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) > 100 nM Positive ALPPL2 expression (ALPPL2+++/++)
Method Description
Anti-ALPPL2 ADC and control ADC were assessed for cytotoxicity in vitro against mesothelioma (M28 and VAMT-1) and control cells (normal human fibroblasts, kidney cells, and primary liver cells).
In Vitro Model Normal HK-2 [Human kidney] cells CVCL_0302
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) > 100 nM Positive ALPPL2 expression (ALPPL2+++/++)
Method Description
Anti-ALPPL2 ADC and control ADC were assessed for cytotoxicity in vitro against mesothelioma (M28 and VAMT-1) and control cells (normal human fibroblasts, kidney cells, and primary liver cells).
In Vitro Model Normal HS775Li cells Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) > 100 nM Positive ALPPL2 expression (ALPPL2+++/++)
Method Description
Anti-ALPPL2 ADC and control ADC were assessed for cytotoxicity in vitro against mesothelioma (M28 and VAMT-1) and control cells (normal human fibroblasts, kidney cells, and primary liver cells).
In Vitro Model Normal HS-27 cells CVCL_0E34
References
Ref 1 ALPPL2 Is a Highly Specific and Targetable Tumor Cell Surface Antigen. Cancer Res. 2020 Oct 15;80(20):4552-4564. doi: 10.1158/0008-5472.CAN-20-1418. Epub 2020 Aug 31.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.